(Q36352095)

13 August 2017

1 reference

title

Chemotherapy for metastatic melanoma (English)

1 reference

13 August 2017

1 reference

1 reference

Marta Mandarà

1

1 reference

13 August 2017

Rolando Nortilli

series ordinal

2

1 reference

13 August 2017

Teodoro Sava

series ordinal

3

1 reference

13 August 2017

Gian Luigi Cetto

series ordinal

4

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

121-130

1 reference

Melanoma epidemic: true or false?

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Skin biopsy rates and incidence of melanoma: population based ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

The changing prognosis of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Phase II trial of fotemustine in patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Combination chemotherapy in metastatic malignant melanoma.A randomized study of three DTIC-containing combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Desmoids in familial adenomatous polyposis are monoclonal proliferations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Use of tamoxifen in the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Angiogenesis-dependent diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Phase II study of thalidomide in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.121

21 January 2018

Identifiers

DOI

10.1586/14737140.6.1.121

1 reference

13 August 2017

1 reference